CO2021001217A2 - Inhibidores tipo indol y azaindol de enzimas pad - Google Patents

Inhibidores tipo indol y azaindol de enzimas pad

Info

Publication number
CO2021001217A2
CO2021001217A2 CONC2021/0001217A CO2021001217A CO2021001217A2 CO 2021001217 A2 CO2021001217 A2 CO 2021001217A2 CO 2021001217 A CO2021001217 A CO 2021001217A CO 2021001217 A2 CO2021001217 A2 CO 2021001217A2
Authority
CO
Colombia
Prior art keywords
indole
inhibitors
pad enzymes
azaindole
azaindole inhibitors
Prior art date
Application number
CONC2021/0001217A
Other languages
English (en)
Spanish (es)
Inventor
Anurag S Srivastava
Khehyong Ngu
Robert J Cherney
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2021001217A2 publication Critical patent/CO2021001217A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2021/0001217A 2018-08-08 2021-02-03 Inhibidores tipo indol y azaindol de enzimas pad CO2021001217A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862715850P 2018-08-08 2018-08-08
PCT/US2019/045466 WO2020033520A1 (en) 2018-08-08 2019-08-07 Indole and azaindole inhibitors of pad enzymes

Publications (1)

Publication Number Publication Date
CO2021001217A2 true CO2021001217A2 (es) 2021-02-26

Family

ID=67766306

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001217A CO2021001217A2 (es) 2018-08-08 2021-02-03 Inhibidores tipo indol y azaindol de enzimas pad

Country Status (18)

Country Link
US (1) US11524959B1 (cg-RX-API-DMAC7.html)
EP (1) EP3833440A1 (cg-RX-API-DMAC7.html)
JP (1) JP7651451B2 (cg-RX-API-DMAC7.html)
KR (1) KR102885181B1 (cg-RX-API-DMAC7.html)
CN (1) CN112805067B (cg-RX-API-DMAC7.html)
AR (1) AR115920A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019319835A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002091A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108791A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000296A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001217A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190462A1 (cg-RX-API-DMAC7.html)
IL (1) IL280650A (cg-RX-API-DMAC7.html)
MX (1) MX2021001565A (cg-RX-API-DMAC7.html)
PE (1) PE20211068A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101174RA (cg-RX-API-DMAC7.html)
TW (1) TW202019415A (cg-RX-API-DMAC7.html)
WO (1) WO2020033520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
CN115298175B (zh) 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
CN111943947B (zh) * 2020-07-24 2021-04-30 重庆文理学院 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
US12492188B2 (en) 2020-08-19 2025-12-09 Bristol-Myers Squibb Company 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
EP4267562A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) * 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
CN117427074B (zh) * 2023-11-13 2026-07-28 山东第一医科大学(山东省医学科学院) 四氢喹啉醇作为铁死亡抑制剂在制备急性肾损伤药物中的应用
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2611010C2 (ru) 2012-07-26 2017-02-17 Глаксо Груп Лимитед 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4
WO2016185279A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107030A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
CN108602812B (zh) 2015-12-22 2021-11-02 坎塞拉有限公司 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物
SG11201807021UA (en) 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
KR102502992B1 (ko) 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
MX2021001471A (es) 2018-08-08 2021-04-28 Bristol Myers Squibb Co Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
EP3833440A1 (en) 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
ES2956090T3 (es) 2018-08-08 2023-12-13 Bristol Myers Squibb Co Inhibidores de bencimidazol de enzimas PAD

Also Published As

Publication number Publication date
KR20210042934A (ko) 2021-04-20
JP7651451B2 (ja) 2025-03-26
BR112021002091A2 (pt) 2021-05-04
CL2021000296A1 (es) 2021-06-25
CN112805067A (zh) 2021-05-14
AR115920A1 (es) 2021-03-10
KR102885181B1 (ko) 2025-11-11
EA202190462A1 (ru) 2021-06-03
SG11202101174RA (en) 2021-03-30
EP3833440A1 (en) 2021-06-16
TW202019415A (zh) 2020-06-01
PE20211068A1 (es) 2021-06-09
US11524959B1 (en) 2022-12-13
AU2019319835A1 (en) 2021-03-25
WO2020033520A1 (en) 2020-02-13
CN112805067B (zh) 2026-04-24
MX2021001565A (es) 2021-04-19
IL280650A (en) 2021-03-25
JP2021534108A (ja) 2021-12-09
CA3108791A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
CO2019011584A2 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos
UY37310A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
CL2020001546A1 (es) Compuestos de 4-azaindol.
CO2020002959A2 (es) Moduladores de piruvato quinasas y uso de los mismos
DOP2019000030A (es) Inhibidores de cdk2/4/6
CO2017003132A2 (es) Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona
UY37537A (es) Derivados de pirazol como inhibidores malt1
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
CO2019005059A2 (es) Inhibidores de magl
ECSP21044843A (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
PE20190446A1 (es) Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
UY33722A (es) Oxazolidinonas como moduladores de mglur5
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
AR100821A1 (es) Pirazolil-triazolil-piridinas como agentes plaguicidas
CR20160180A (es) Compuestos heterocíclicos de n-acilimino
CO2022002022A2 (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias